Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Specimen Handling 273Magnetic Resonance Spectroscopy 226pembrolizumab 218Carboplatin 174Biopsy 164Cisplatin 157Nivolumab 155Cyclophosphamide 139Radiotherapy 121Paclitaxel 120Gemcitabine 113durvalumab 90Bevacizumab 89Dexamethasone 82Rituximab 81Oxaliplatin 77venetoclax 73atezolizumab 70Doxorubicin 70Docetaxel 66Radiosurgery 65Fluorouracil 65Ipilimumab 64Capecitabine 64Etoposide 62Radiation 59Prednisone 59Cytarabine 59Lenalidomide 56fludarabine 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Robotics × 90 days × Clear all
NCT07025369 2026-03-13

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

Mayo Clinic

Phase 2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡